Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

By sjmartinez • June 9, 2024

Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun;19(6):928-940. doi: 10.1016/j.jtho.2024.01.012. Epub 2024 Jan 24. PMID: 38278303.

Tags: Adverse events, Cedars Sinai DoM, chemotherapy, durvalumab, EGFR, Hematology/Oncology, Non–small cell lung cancer, Osimertinib, Publications, targeted therapy

Topic Mapping to Inform Content to Discuss in Shared Decision-Making for Prostate Cancer

Friedrich NA, Kokorowski P, Luu M, Chaplin A, Polineni R, Shiang A, Shin D, Tan J, Freedland SJ, Spiegel B, Daskivich TJ. Topic Mapping to[...]

Long-Term Outcomes Following Catheter-Based Therapies in Older Adults With Acute Pulmonary Embolism

Watanabe A, Kuno T, Miyamoto Y, Ueyama HA, Gotanda H, Bangalore S, Tsugawa Y. Long-Term Outcomes Following Catheter-Based Therapies in Older Adults With Acute Pulmonary[...]

Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective

Wilkinson MJ, Bijlani P, Davidson MH, Duell PB, Horan M, Malloy MJ, Newfield RS, Pradeep P, Shah PK, Stock EO, Warden BA, Ito MK. Real-World[...]